Adaptive Pre-Surgery Therapy for Patients with Localized Pancreatic Cancer
Will a flexible approach to neoadjuvant treatment work better for pancreatic cancer patients with tumors that can be removed surgically?
Will a flexible approach to neoadjuvant treatment work better for pancreatic cancer patients with tumors that can be removed surgically?
Is chemotherapy before and after pancreatic cancer surgery more effective than just chemotherapy after surgery?
A clinical trial tests the safety and effectiveness of tumor-associated antigen-specific cytotoxic T lymphocytes, which target specific tumor proteins.
A new clinical trial adds vitamin D to standard of care chemotherapy before surgery, to make pancreatic cancer tumors more removable.
Can a combination of radiation and chemotherapy make pancreatic tumors that are borderline removeable better candidates for surgery? A clinical trial looks at this question.
A clinical trial looks at the effectiveness of PEGPH20 in helping chemotherapy penetrate the stroma of pancreatic tumors, to make them removable.
Can neoadjuvant treatment such as chemoradiation make pancreatic cancer removal surgery more effective? That is the question asked by this clinical trial.
A clinical trial combines immunotherapy, common treatments, an antiretroviral drug, and SBRT for locally advanced pancreatic cancer.
A clinical trial looks at immunotherapy plus vitamin D plus standard chemotherapy before surgery to remove pancreatic cancer.
A clinical trial compares the effectiveness of two different types of immunotherapy with standard treatment after pancreatic cancer surgery.